Chemistry: molecular biology and microbiology – Spore forming or isolating process
Patent
1994-08-10
1997-06-24
Feisee, Lila
Chemistry: molecular biology and microbiology
Spore forming or isolating process
4352402, 4352401, 43524025, 424 9371, C12N 506
Patent
active
056416776
ABSTRACT:
The present invention provides a method for enhancing the immunotherapeutic activity, e.g., cytotoxicity, of immune cells by depleting immune cells of a cell subset that down-regulates the immune response, such as either CD4.sup.+ or CD8.sup.+ lymphocytes. The remaining depleted immune cells are then cultured in the presence of interleukin-2 (IL-2) and an antibody to a lymphocyte surface receptor, preferably an anti-CD3 monoclonal antibody (MoAb). The present invention also provides a method of enhancing the immunotherapeutic activity, e.g., cytotoxicity, of immune cells by culturing immune cells in the presence of IL-2 and an antibody to a lymphocyte surface receptor, preferably an anti-CD3 MoAb; separating a cell subset capable of developing immunotherapeutic activity, e.g., cytotoxicity, from the cultured immune cells, e.g., either CD4.sup.+ or CD8.sup.+ lymphocytes; and then subculturing the separated lymphocytes in the presence of IL-2.
REFERENCES:
patent: 4690915 (1987-09-01), Rosenberg
patent: 4808151 (1989-02-01), Dunn et al.
Tsoukas et al., "Activation of Resting T Lymphocytes By Anti-CD3 (T3) Antibodies in the Absence of Monocytes", The Journal of Immunology, vol. 135, No. 3, Sep. 1985, pp. 1719-1723.
Hogan et al., "Lymphokine-Activated and Natural Killer Cell Activity in Human Intestinal Mucosa", The Journal of Immunology, vol. 135, No. 3, Sep. 1985, pp. 1731-1738.
P.M. Anderson et al., Cancer Immunol. Immunother., 1988, 27, 82, "Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2".
P.M. Anderson et al., J. Immunol., 1989, 142, 1383, "Anti-CD3.sup.+ IL-2-Stimulated Murine Killer Cells in Vitro Generation and In Vivo Antitumor Activity".
L.S. Davis et al., Cell Immunol., 1989, 118, 208, "T Cell Activation Induced by Anti-CD3 Antibodies Requires Prolonged Stimulation of Protein Kinase C".
Dianzani et al., Eur. J. Immunol., 19: 1037 (1989), "CD8.sup.+ CD11b+ peripheral blood T lymphocytes contain lymphokine-activated killer cell precursors".
Geller et al., J. Immunol., 146(10): 3280 (1991), "Generation of Lymphokine Activated Killer Activity in T Cells".
T.D. Geppert et al., J. Clin. Invest., 1988, 81, 1497, "Activation of T Lymphocytes by Immobilized Monoclonal Antibodies to CD3".
E.A. Grimm et al., J. Exp. Med., 1982, 155, 1823, "Lymphokine-Activated Killer Cells Phenomenon".
M. Izquierdo et al., Clin. Exp. Immunol., 1988, 74, 300, "Selection T cell subset depletion with anti-CD4 and anti-CD8 intact ricin immunotoxins".
C.M. Loeffler et al., Cancer Res., 51:2127 (1991), "Antitumor Effects of Interleukin 2 Liposomes and Anti-CD3-Stimulated T-Cells Against Murine MCA-38 Hepatic Metastasis".
E. Lotzova et al., Nat. Immun. Cell Growth Regul., 1987, 8, 219, "Augmentation of Antileukemia Lytic Activity by OKT3 Monoclonal Antibody: Synergism of OKT3 and Interleukin-2".
A.C. Ochoa et al., Cancer Res., 49: 963 (1989), "Lymphokine-activated Killer Activity in Long-Term Cultures with Anti-CD3 plus Interleukin 2: Identification and Isolation of Effector Subsets".
A.C. Ochoa et al., J. Immunol., 1987, 138, 2728, "Long-Term Growth of Lymphokine-Activated Killer (LAK) Cells: Role of Anti-CD3, .beta.-IL 1, Interferon-.gamma. and -.beta.".
L.E. Samelson et al., Proc. Natl. Acad. Sci. USA, 87: 4358 (1990), "Association of the fyn protein-tyrosine kinase with the T-cell antigen receptor".
R. Schwab et al., J. Immunol., 1985, 135, 1714, "Requirements for T-Cell Activation by OKT3 Monoclonal Antibody: Role of Modulation of T3 Molecules and Interleukin".
S. Shu et al., J. Immunol., 1985, 135, 2895, "Adoptive Immunotherapy of a Newly Induced Sarcoma: Immunlogic Characteristics of Effector Cells".
Smyth, J. Exp. Med, 171: 1269 (1990),"Interleukin 2 Induction of Pure-Forming Protein Gene Expression in Human Peripheral Blood CD8.sup.+ T Cells".
Smyth, J. Immunol., 148: 3289 (1991), "Regulation of Lymphokine-Activated Killer Activity and Pore-forming Protein Gene Expression in Huan Peripheral Blood CD8.sup.+ T Lymphocytes".
C.-C. Ting et al., Immunol. Invest., 1990, 19, 347, "Anti-CD3 Antibody-Induced Activated Killer Cells Subsets of Killer Cells that Mediate Fast or Slow Lytic Reactions".
M. C. Turco et al., Blood, 1989, 74, 1651, Proliferative Pathways in CD1.sup.- CD3.sup.+ CD4.sup.+ CD8.sup.+ T Prolymphocytic Leukemic Cells: Analysis with Monoclonal Antibodies and Cytokines.
R. J. van de Griend et al., J. Immunol., 1987, 138, 1627, "Lysis of Tumor Cells by CD3.sup.+ 4.sup.- 8.sup.- 16.sup.+ T Cell Receptor .alpha..beta.-Clones, Regulated Via CD3 and CD16 Activation Sites, Recombinant Interleukin 2, and Interferon .beta.".
W. H. West et al., J. Immunol., 1977, 118, 355, "Natural Cytotoxic Reactivity of Human Lymphocytes Against a Myeloid Cell Line: Characterization of Effector Cells".
Ochas et al., FASEB Journal, 3(3)A: 826 (abstract) (1989), "T Cels Can Develop High Lak Activity: Possible Regulatory Circuits".
Lotze et al., Cancer Res., 41: 4420 (1981), "Lysis of Fresh and Cultured Autologous Tumor by Human Lymphocytes Cultured in T-Cell Growth Factor".
Balldegrun et al., Cancer Res., 48: 206 (1988), "Interleukin 2 Expanded Tumor-infiltrating Lymphocytes in Human Renal Cell Cancer: Isolation, Characterization, and Antitumor Activity".
Maghazachi et al., J. Immunol., 141: 4039 (1988), "Influence of T Cells on the Expression of Lymphokine-Activated Killer Cell Activity and In Vivo Tissue Distribution".
Damle et al., J. Exp. Med., 158: 159 (1983), "Immunoregulatory T Cell Circuits in Man".
Lewis et al., PNAS, USA, 85: 9743 (1988), "Restricted production of interleukin 4 by activated human T cells".
Halvorsen et al., Scand J. Immunol. 27, 555-563, 1988, "Role of Accessory Cells in the Activation of Pure T Cells via the T Cell Receptor-CD3 Complex or with Phytohaemaggloutnin".
Halvorsen et al., Scand J. Immunol. 26, 197-205, 1987, "Activation of Resting, Pure CD4.sup.+, and CD8.sup.+ Cells via CD3".
Curti et al. J. Clin. Oncol. 11:652-660 (1993).
Whiteside et al. Cancer Immunol Immunother 39: 14-22 (1994).
Strome et al. J. Hematotherpy 2:63-73 (1993).
Michih Immunol Ser 61: 293-309 (1994).
Votze Cell Transplantation 2: 33-47 (1993).
Lindemann et al. Blut 59: 375-384 (1989).
Teichmann et al. Nat Immun 11: 117-132 (1992).
Ochos et al. Cancer Research 49: 963-968 (1989).
Bieva et al. Exp Hematol 17: 914-920 (1989).
Smyth, et al.; Journal of Experimental Medicine, vol. 171, pp. 1269-1281; Apr. 1990.
Ochoa, et al. "Long-Term Growth of Lymphokine-Activated Killer (LAK) Cell 59 Role of Anti-CD3, B-IL9, Interferon-.gamma. and -.beta." The Journal of Immunology, vol. 138, No. 8, pp. 2728-2733 1987.
Ochoa, et al. T Cells Can Develop High LAK Activity: Possible Regulatory Circuits FASEB Journal, vol. 3, No. 3 (Pt. 1), A826 (Abstract) 1989.
Geller, et al. Generation of Lymphokine-Activated Killer Activity in T Cells --Possible Regulatory Circuits The Journal of Immunology, vol. 146, No. 10, pp. 3280-3288 1991.
Bach Fritz H.
Geller Robin Lee
Ochoa Augusto Carlos
Feisee Lila
Gambel Phillip
Regents of the University of Minnesota
LandOfFree
Method of enhancing the immunotherapeutic activity of immune cel does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of enhancing the immunotherapeutic activity of immune cel, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of enhancing the immunotherapeutic activity of immune cel will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-148695